New thiazolidinediones affect endothelial cell activation and angiogenesis

European Journal of Pharmacology

Volumn 782, Issue , 2016, Pages 98-106

  Rudnicki, Martina ^a   Tripodi, Gustavo L ^a   Ferrer, Renila ^a   Boscá, Lisardo ^b   Pitta, Marina G R ^c   Pitta, Ivan R ^c   Abdalla, Dulcineia S P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Angiogenesis; Endothelial cells; Inflammation; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 BIPHENYL 4 YLMETHYL 5 (4 NITRO BENZYLIDENE) THIAZOLIDINE 2,4 DIONE; 4 AMINO 5 METHYLAMINO 2',7' DIFLUOROFLUORESCEIN; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MESSENGER RNA; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; [5 (4 CHLORO BENZYLIDENE) 3 (2,6 DICHLORO BENZYL) THIAZOLIDINE 2,4 DIONE]; [5 (5 BROMO 1H INDOL 3 YLMETHYLENE) 3 (4 CHLOROBENZYL) THIAZOLIDINE 2,4 DIONE]; CELL ADHESION MOLECULE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CELL MIGRATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; PRIORITY JOURNAL; REPORTER GENE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; AGONISTS; CELL MOTION; CELL SURVIVAL; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; INTRACELLULAR SPACE; METABOLISM;

CELL ADHESION MOLECULES; CELL MOVEMENT; CELL SURVIVAL; DOWN-REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTRACELLULAR SPACE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PPAR GAMMA; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964577839     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.04.038     Document Type: Article

References (44)

1. A. Aljada, L. O'Connor, Y.Y. Fu, and S.A. Mousa PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis Angiogenesis 11 2008 361 367
2. D.A. Antonetti, R. Klein, and T.W. Gardner Diabetic retinopathy N. Engl. J. Med. 366 2012 1227 1239
3. F. Biscetti, E. Gaetani, A. Flex, T. Aprahamian, T. Hopkins, G. Straface, G. Pecorini, E. Stigliano, R.C. Smith, F. Angelini, J.J. Castellot Jr., and R. Pola Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism Diabetes 57 2008 1394 1404
4. D. Bishop-Bailey, and K.E. Swales The role of PPARs in the endothelium: implications for cancer therapy PPAR Res. 2008 2008 904251
5. M.G. Bonini, R.P. Mason, and O. Augusto The mechanism by which 4-hydroxy-2,2,6,6-tetramethylpiperidene-1-oxyl (tempol) diverts peroxynitrite decomposition from nitrating to nitrosating species Chem. Res. Toxicol. 15 2002 506 511
6. A.J. Boulton, R.S. Kirsner, and L. Vileikyte Clinical practice. Neuropathic diabetic foot ulcers N. Engl. J. Med. 351 2004 48 55
7. D.S. Calnek, L. Mazzella, S. Roser, J. Roman, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells Arterioscler. Thromb. Vasc. Biol. 23 2003 52 57
8. B. Cariou, B. Charbonnel, and B. Staels Thiazolidinediones and PPARgamma agonists: time for a reassessment Trends Endocrinol. Metab. 23 2012 205 215
9. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 2011 298 307
10. Carpentier, G., 2012. ImageJ contribution: Angiogenesis Analyzer. ImageJ News.
11. G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G.P. Fadini, M. Albiero, A. Semplicini, and A. Avogaro Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism Arterioscler. Thromb. Vasc. Biol. 27 2007 2627 2633
12. F.A. Cesar, M. Rudnicki, H.B. de Las, L. Bosca, M.C. Lima, I.R. Pitta, and D.S. Abdalla New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice Vasc. Pharmacol. 71 2015 174 180
13. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R.M. Evans PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat. Med. 7 2001 48 52
14. K. Chu, S.T. Lee, J.S. Koo, K.H. Jung, E.H. Kim, D.I. Sinn, J.M. Kim, S.Y. Ko, S.J. Kim, E.C. Song, M. Kim, and J.K. Roh Peroxisome proliferator-activated receptor-gamma-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia Brain Res. 1093 2006 208 218
15. F. Denizot, and R. Lang Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89 1986 271 277
16. V. Falanga Wound healing and its impairment in the diabetic foot Lancet 366 2005 1736 1743
17. D.L. Feinstein, A. Spagnolo, C. Akar, G. Weinberg, P. Murphy, V. Gavrilyuk, and R.C. Dello Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70 2005 177 188
18. K. Fujisawa, T. Nishikawa, D. Kukidome, K. Imoto, T. Yamashiro, H. Motoshima, T. Matsumura, and E. Araki TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis Biochem. Biophys. Res. Commun. 379 2009 43 48
19. O. Gealekman, A. Burkart, M. Chouinard, S.M. Nicoloro, J. Straubhaar, and S. Corvera Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production Am. J. Physiol. Endocrinol. Metab. 295 2008 E1056 E1064
20. C. Golias, E. Tsoutsi, A. Matziridis, P. Makridis, A. Batistatou, and K. Charalabopoulos Review. Leukocyte and endothelial cell adhesion molecules in inflammation focusing on inflammatory heart disease In Vivo 21 2007 757 769
21. S. Koch, and L. Claesson-Welsh Signal transduction by vascular endothelial growth factor receptors Cold Spring Harb. Perspect. Med 2 2012 a006502
22. G.K. Kolluru, S.C. Bir, and C.G. Kevil Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing Int. J. Vasc. Med 2012 2012 918267
23. S. Kurebayashi, X. Xu, S. Ishii, M. Shiraishi, H. Kouhara, and S. Kasayama A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells Atherosclerosis 182 2005 71 77
24. M. Laakso, and J. Kuusisto Insulin resistance and hyperglycaemia in cardiovascular disease development Nat. Rev. Endocrinol. 10 2014 293 302
25. A. Li, M.L. Varney, J. Valasek, M. Godfrey, B.J. Dave, and R.K. Singh Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis Angiogenesis 8 2005 63 71
26. C.C. Liang, A.Y. Park, and J.L. Guan In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat. Protoc. 2 2007 329 333
27. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408
28. J.O. Lundberg, M.T. Gladwin, and E. Weitzberg Strategies to increase nitric oxide signalling in cardiovascular disease Nat. Rev. Drug Discov. 2015
29. R. Nagahama, T. Matoba, K. Nakano, S. Kim-Mitsuyama, K. Sunagawa, and K. Egashira Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia Arterioscler. Thromb. Vasc. Biol. 32 2012 2427 2434
30. D. Panigrahy, S. Singer, L.Q. Shen, C.E. Butterfield, D.A. Freedman, E.J. Chen, M.A. Moses, S. Kilroy, S. Duensing, C. Fletcher, J.A. Fletcher, L. Hlatky, P. Hahnfeldt, J. Folkman, and A. Kaipainen PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis J. Clin. Invest. 110 2002 923 932
31. E. Pardali, M.J. Goumans, and D.P. ten Signaling by members of the TGF-beta family in vascular morphogenesis and disease Trends Cell Biol. 20 2010 556 567
32. V. Pasceri, H.D. Wu, J.T. Willerson, and E.T. Yeh Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators Circulation 101 2000 235 238
33. Pitta, I.R., Galdino, S.L., Lima, M.C.A., 2007. Preparation of 2,4-thiazolidinedione derivatives having hypoglycemic activity. (BR 2006001826 A). Ref Type: Patent
34. J.A. Polikandriotis, L.J. Mazzella, H.L. Rupnow, and C.M. Hart Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms Arterioscler. Thromb. Vasc. Biol. 25 2005 1810 1816
35. C. Rask-Madsen, and G.L. King Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes Nat. Clin. Pract. Endocrinol. Metab. 3 2007 46 56
36. C. Rask-Madsen, and G.L. King Vascular complications of diabetes: mechanisms of injury and protective factors Cell Metab. 17 2013 20 33
37. L.A. Ridnour, J.S. Isenberg, M.G. Espey, D.D. Thomas, D.D. Roberts, and D.A. Wink Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1 Proc. Natl. Acad. Sci. USA 102 2005 13147 13152
38. J.R. Santin, M. Daufenback, I. Rodrigues, S.F. Teixeira, S. Muscara, M.N. Lins, G.S. da,R.P., I, and S.H. Farsky Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions PLoS One 8 2013 e76894
39. J.R. Santin, F.D. Uchoa, M.C. Lima, M.M. Rabello, I.D. Machado, M.Z. Hernandes, A.A. Amato, F.A. Milton, P. Webb, F.A. Neves, S.L. Galdino, I.R. Pitta, and S.H. Farsky Chemical synthesis, docking studies and biological effects of a pan peroxisome proliferator-activated receptor agonist and cyclooxygenase inhibitor Eur. J. Pharm. Sci. 48 2013 689 697
40. S.W. Schaffer, C.J. Jong, and M. Mozaffari Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited Vasc. Pharmacol. 57 2012 139 149
41. E. Scoditti, M. Massaro, M.A. Carluccio, A. Distante, C. Storelli, and C.R. De PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium Cardiovasc. Res. 86 2010 302 310
42. N. Wang, L. Verna, N.G. Chen, J. Chen, H. Li, B.M. Forman, and M.B. Stemerman Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells J. Biol. Chem. 277 2002 34176 34181
43. X. Xin, S. Yang, J. Kowalski, and M.E. Gerritsen Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo J. Biol. Chem. 274 1999 9116 9121
44. R. Zent, and A. Pozzi Angiogenesis in diabetic nephropathy Semin. Nephrol. 27 2007 161 171